CNT-DM-02

CNT-DM-02 is a peptide-based synthetic molecule currently under development by Centurion (Centurion Pharma) for the treatment of diabetes-related metabolic disorders. Classified within the Alimentary & Metabolism therapeutic category, the drug is designed for administration via a pen injector, a delivery system typically utilized for glucagon-like peptide-1 (GLP-1) receptor agonists or insulin analogs. As part of Centurion's biotechnology-focused pipeline, CNT-DM-02 likely represents a biosimilar or a value-added synthetic peptide aimed at managing glycemic control in patients with type 2 diabetes mellitus. The development of this asset aligns with the company's strategy to provide advanced, high-tech therapeutic options in the Turkish and global pharmaceutical markets.